萨瓦拉制药
SVRA
4.45
-0.29
-6.12%
萨瓦拉制药
US · SVRA
#3247 按市值排名
4.45
-0.29
-6.12%
实时 - 追踪5344个代码 - 心跳于152秒前
· 2026-10-16 20:01
最新新闻
-
评级变动
Guggenheim Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $11\u5e02\u573a\u8d44\u8baf · 2025/12/23
-
评级变动
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $9\u5e02\u573a\u8d44\u8baf · 2025/11/14
-
评级变动
Guggenheim Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11\u5e02\u573a\u8d44\u8baf · 2025/9/9
-
评级变动
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $11\u5e02\u573a\u8d44\u8baf · 2025/10/14
-
评级变动
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9\u5e02\u573a\u8d44\u8baf · 2026/4/16
-
评级变动
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11\u5e02\u573a\u8d44\u8baf · 2026/6/3
-
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10\u5e02\u573a\u8d44\u8baf · 2026/8/13
-
评级变动
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9\u5e02\u573a\u8d44\u8baf · 2026/5/22
-
评级变动
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $8\u5e02\u573a\u8d44\u8baf · 2025/11/14
-
评级变动
Citizens JMP Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11\u5e02\u573a\u8d44\u8baf · 2025/10/23
-
评级变动
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10\u5e02\u573a\u8d44\u8baf · 2026/5/21
-
Guggenheim Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11\u5e02\u573a\u8d44\u8baf · 2026/8/21
-
评级变动
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9\u5e02\u573a\u8d44\u8baf · 2026/5/16
-
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
评级变动
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11\u5e02\u573a\u8d44\u8baf · 2026/4/11
-
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16\u5e02\u573a\u8d44\u8baf · 2026/8/26
-
评级变动
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11\u5e02\u573a\u8d44\u8baf · 2026/4/25
-
评级变动
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $16\u5e02\u573a\u8d44\u8baf · 2026/5/13
-
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10\u5e02\u573a\u8d44\u8baf · 2026/6/15
-
评级变动
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10\u5e02\u573a\u8d44\u8baf · 2025/12/23
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 20:01:08 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
萨瓦拉制药 讨论区 0 条评论